Cargando…
LETTER TO THE EDITOR Subcutaneous (SC) Methotrexate (MTX) is Better and Well-Tolerable than Oral MTX in Rheumatoid Arthritis Patients, Switched from Oral to SC Administration Due to Gastrointestinal Side Effects
Autores principales: | Borman, Pinar, Demir, Gülseren, Kaygısız, Ferda, Okumuş, Muyesser |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157341/ https://www.ncbi.nlm.nih.gov/pubmed/25232363 http://dx.doi.org/10.2174/1874312901408010018 |
Ejemplares similares
-
Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX
por: Verkaaik, M, et al.
Publicado: (2011) -
Monoclonal antibody targeting of methotrexate (MTX) against MTX-resistant tumour cell lines.
por: Affleck, K., et al.
Publicado: (1992) -
Impairment of Methotrexate (MTX)‐Polyglutamate Formation of MTX‐resistant K562 Cell Lines
por: Koizumi, Shoichi
Publicado: (1988) -
Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World
por: Zhang, Le, et al.
Publicado: (2020) -
How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?—MTX in the Treat-to-Target Strategy
por: Taylor, Peter. C., et al.
Publicado: (2019)